Daniela Lee Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniela Lee Smith has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Adel T. Aref
ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia
36 shared publications - Amy Sheen
New South Wales Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia
36 shared publications - Anthony J. Gill
Sydney Medical School, University of Sydney, Sydney
36 shared publications - Asim Anees
The University of Sydney 1 ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health Westmead, Australia
36 shared publications - Daniel Bucio-Noble
The University of Sydney 1 ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health Westmead, Australia
36 shared publications - Dylan Xavier
Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Australia
36 shared publications
Latest Publications
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Proteomic risk score for mortality. A, Forest plot detailing the multivariable HRs for the overall survival of each of the proteins used to build the proteomic risk score. B, Kaplan–Meier curve displaying the overall survival probability of the low- and high-risk groups within our cohort. C, Kaplan–Meier curve displaying the survival probability of the low- and high-risk groups within the CPTAC validation dataset.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Proteomic risk score for mortality. A, Forest plot detailing the multivariable HRs for the overall survival of each of the proteins used to build the proteomic risk score. B, Kaplan–Meier curve displaying the overall survival probability of the low- and high-risk groups within our cohort. C, Kaplan–Meier curve displaying the survival probability of the low- and high-risk groups within the CPTAC validation dataset.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 7 shows the list of differentially abundant proteins (DAP) and their associated biological pathways, as well as the potential drug targets among each COSMIC signature of interest. Note that no patients showed positivity for COSMIC signatures 1,6,20,25,26, while COSMIC signatures 13, 18, 28, and 30 had only one patient in the positive group.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 7 shows the list of differentially abundant proteins (DAP) and their associated biological pathways, as well as the potential drug targets among each COSMIC signature of interest. Note that no patients showed positivity for COSMIC signatures 1,6,20,25,26, while COSMIC signatures 13, 18, 28, and 30 had only one patient in the positive group.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 9: Kaplan-Meier plot for patients dichotomized by a proteomic risk score that uses only the ten proteins detected in blood by mass spectrometry (PURB, GALM, SERPINA3, OAS3, KRT2, NUDT2, SERPINA4, CUTA, POSTN, CLEC11A).
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 9: Kaplan-Meier plot for patients dichotomized by a proteomic risk score that uses only the ten proteins detected in blood by mass spectrometry (PURB, GALM, SERPINA3, OAS3, KRT2, NUDT2, SERPINA4, CUTA, POSTN, CLEC11A).
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 5 shows the proteomic information for the 18 risk-score proteins. (A) Peptide detection rate within the dataset. (B) Protein Missingness in our tumor data only. (C) Protein Missingness in the CPTAC Pancreatic Cancer Cohort.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 5 shows the proteomic information for the 18 risk-score proteins. (A) Peptide detection rate within the dataset. (B) Protein Missingness in our tumor data only. (C) Protein Missingness in the CPTAC Pancreatic Cancer Cohort.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 11 shows the differential abundance and pathway enrichment analyses based on the KRAS-G12C status. (A) Volcano plot displaying the differentially abundant proteins between tumors harboring the KRAS-G12C mutation versus any other KRAS-G12 mutation. (B) Pathways enriched in the KEGG, Reactome, and WikiPathways databases based on the upregulated proteins from tumors that harbored KRAS-G12C mutations when compared to tumors with other KRAS12 mutations.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 11 shows the differential abundance and pathway enrichment analyses based on the KRAS-G12C status. (A) Volcano plot displaying the differentially abundant proteins between tumors harboring the KRAS-G12C mutation versus any other KRAS-G12 mutation. (B) Pathways enriched in the KEGG, Reactome, and WikiPathways databases based on the upregulated proteins from tumors that harbored KRAS-G12C mutations when compared to tumors with other KRAS12 mutations.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 6 shows the results of the univariate and multivariate Cox regression model with Stepwise-AIC, showing the association of each of the COSMIC signatures with overall survival in the study cohort. Note that all patients showed positivity for COSMIC signature 1, while no patients showed positivity for COSMIC signatures 6, 20, 25, and 26. For COSMIC signatures 13, 18, 28, and 30, only one patient was in the positive group.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 6 shows the results of the univariate and multivariate Cox regression model with Stepwise-AIC, showing the association of each of the COSMIC signatures with overall survival in the study cohort. Note that all patients showed positivity for COSMIC signature 1, while no patients showed positivity for COSMIC signatures 6, 20, 25, and 26. For COSMIC signatures 13, 18, 28, and 30, only one patient was in the positive group.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 5 shows the distribution of clinical variables in the study cohort across the two proteomic-based risk score groups. Gln61Arg: Glutamine to Arginine at position 61, Gln61His: Glutamine to Histidine at position 61, Gly12Ala: Glycine to Alanine at position 12, Gly12Arg: Glycine to Arginine at position 12, Gly12Asp: Glycine to Aspartic Acid at position 12, Gly12Cys: Glycine to Cysteine at position 12, Gly12Leu: Glycine to Leucine at position 12, Gly12Val: Glycine to Valine at position 12. Note that all patients showed positivity for COSMIC signature 1, while no patients showed positivity for COSMIC signatures 6, 20, 25, and 26. For COSMIC signatures 13, 18, 28, and 30, only one patient was in the positive group.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 5 shows the distribution of clinical variables in the study cohort across the two proteomic-based risk score groups. Gln61Arg: Glutamine to Arginine at position 61, Gln61His: Glutamine to Histidine at position 61, Gly12Ala: Glycine to Alanine at position 12, Gly12Arg: Glycine to Arginine at position 12, Gly12Asp: Glycine to Aspartic Acid at position 12, Gly12Cys: Glycine to Cysteine at position 12, Gly12Leu: Glycine to Leucine at position 12, Gly12Val: Glycine to Valine at position 12. Note that all patients showed positivity for COSMIC signature 1, while no patients showed positivity for COSMIC signatures 6, 20, 25, and 26. For COSMIC signatures 13, 18, 28, and 30, only one patient was in the positive group.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 3 shows the differentially abundant proteins, their associated pathways, and the potential drug targets identified across the four proteomic-based clusters.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Table 3 shows the differentially abundant proteins, their associated pathways, and the potential drug targets identified across the four proteomic-based clusters.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 6 shows a forest plot detailing the hazard ratio of the proteomic risk score and clinically relevant variables for PDA within our study cohort using multivariable Cox regression modeling.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Supplementary Figure 6 shows a forest plot detailing the hazard ratio of the proteomic risk score and clinically relevant variables for PDA within our study cohort using multivariable Cox regression modeling.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Clinical variables across the proteomic-based risk groups.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
Clinical variables across the proteomic-based risk groups.